Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality, pricey and fading Quality Strong, Valuation Expensive, Momentum Bearish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #42 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 17 Jun 2026 | WHITEOAK CAPITAL MUTUAL FUND | Block | Buy | 145,000 | 1730.0000 | NSE |
| 17 Jun 2026 | TCW WHITE OAK EMERGING MARKETS EQUITY FUND | Block | Buy | 1,920 | 1730.0000 | NSE |
| 17 Jun 2026 | SEPIA INVESTMENTS LIMITED | Block | Sell | 4,328,943 | 1730.0000 | NSE |
| 17 Jun 2026 | KOTAK MAHINDRA MUTUAL FUND | Block | Buy | 161,861 | 1730.0000 | NSE |
| 17 Jun 2026 | INVESCO MUTUAL FUND | Block | Buy | 289,017 | 1730.0000 | NSE |
| 17 Jun 2026 | INDIA ACORN ICAV - ASHOKA WHITEOAK EMERGING MARKETS EQUITY FUND | Block | Buy | 148,686 | 1730.0000 | NSE |
| 17 Jun 2026 | HDFC MUTUAL FUND | Block | Buy | 2,450,000 | 1730.0000 | NSE |
| 17 Jun 2026 | FACTORY MUTUAL INSURANCE COMPANY | Block | Buy | 10,670 | 1730.0000 | NSE |
| 17 Jun 2026 | ASHOKA WHITEOAK EMERGING MARKETS EQUITY EX CHINA FUND | Block | Buy | 29,520 | 1730.0000 | NSE |
| 17 Jun 2026 | ANCHOR PARTNERS | Block | Sell | 161,861 | 1730.0000 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 19 Jun 2026 | Dividend - Rs 10 Per Share | 10.0000 | 19 Jun 2026 |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 31 Jul 2026 | Financial Results | Yes |
| 11 May 2026 | Financial Results/Dividend | Yes |
| 2 Feb 2026 | Financial Results | Yes |
| 2 Jan 2026 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 30 Sep 2026 | Company Update | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Credit Rating |
| 30 Sep 2026 | Credit Rating | CORONA Remedies Limited has informed the Exchange about Credit Rating |
| 28 Sep 2026 | Insider Trading / SAST | Corona Remedies Ltd - 544644 - Closure of Trading Window |
| 28 Sep 2026 | Trading Window | CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 19 Sep 2026 | Insider Trading / SAST | Corona Remedies Ltd - 544644 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 |
| 19 Sep 2026 | Insider Trading / SAST | Corona Remedies Ltd - 544644 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 |
| 18 Sep 2026 | Company Update | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 18 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | CORONA Remedies Limited has informed the Exchange about Schedule of meet |
| 10 Sep 2026 | Company Update | Corona Remedies Ltd - 544644 - Clarification On Movement In Volume |
| 10 Sep 2026 | Company Update | Corona Remedies Ltd - 544644 - Clarification sought from Corona Remedies Ltd |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
